Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today provided an update on the company’s Talvesta(TM) (talotrexin) for Injection clinical program. Hana is conducting multiple clinical trials with Talvesta in order to evaluate the most appropriate dose, schedule of administration, and Talvesta’s activity in multiple cancers.
